David Tsao, an officer and director at BillionToOne, Inc., has filed a notice to sell 20,000 shares of the company's Class A stock. This filing, dated November 2, 2026, highlights Tsao's ongoing engagement with his stock holdings, suggesting a strategic approach to personal investments.

BillionToOne, Inc. operates in the medical laboratories sector, which is characterized by its focus on providing various laboratory services. The company is incorporated in Delaware and has its business address in Menlo Park, California. Tsao's recent filing is part of a series of stock transactions that he has conducted over the past few months.

According to the filing, Tsao's decision to sell these shares comes after exercising stock options. The filing states, “Nature of Acquisition Transaction: Stock Option Exercise.” This indicates that Tsao is converting his options into shares and then selling them, a common practice among executives managing their stock portfolios.

The sale of 20,000 shares has an aggregate market value of approximately $2,266,400, based on the current market conditions. This transaction is expected to impact Tsao's personal financial situation, as well as reflect on the market's perception of BillionToOne's stock performance.

In the past three months, Tsao has been active in the market, selling shares on multiple occasions. Notably, he sold 10,000 shares on August 10, 2026, for gross proceeds of $928,600, and another 20,000 shares on October 5, 2026, for $2,162,950. These transactions indicate a pattern of liquidating portions of his holdings, which may influence investor sentiment regarding the company's future.

As a significant player in the medical laboratories sector, BillionToOne, Inc. may face scrutiny from industry observers and competitors regarding Tsao's stock sales. The filing does not specify what actions may follow this transaction, but it highlights the ongoing activity of Tsao in managing his investment portfolio.

The filing does not say what happens next.